QuidelOrtho Corporation (QDEL)
- Previous Close
40.82 - Open
40.75 - Bid 38.95 x 200
- Ask 39.07 x 100
- Day's Range
38.94 - 40.75 - 52 Week Range
37.78 - 95.02 - Volume
334,075 - Avg. Volume
1,149,545 - Market Cap (intraday)
2.609B - Beta (5Y Monthly) 0.12
- PE Ratio (TTM)
-- - EPS (TTM)
-0.15 - Earnings Date May 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
59.00
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
www.quidelortho.comRecent News: QDEL
Performance Overview: QDEL
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QDEL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QDEL
Valuation Measures
Market Cap
2.73B
Enterprise Value
5.18B
Trailing P/E
--
Forward P/E
14.93
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.91
Price/Book (mrq)
0.55
Enterprise Value/Revenue
1.73
Enterprise Value/EBITDA
8.53
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.34%
Return on Assets (ttm)
2.01%
Return on Equity (ttm)
-0.20%
Revenue (ttm)
3B
Net Income Avi to Common (ttm)
-10.1M
Diluted EPS (ttm)
-0.15
Balance Sheet and Cash Flow
Total Cash (mrq)
167.5M
Total Debt/Equity (mrq)
52.36%
Levered Free Cash Flow (ttm)
335.98M
Research Analysis: QDEL
Company Insights: QDEL
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: QDEL
QDEL: What does Argus have to say about QDEL?
QUIDELORTHO CORP has an Investment Rating of SELL; a target price of $32.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetQDEL: Lowering target price to $32.00
QUIDELORTHO CORP has an Investment Rating of SELL; a target price of $32.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetQDEL: Raising target price to $36.00
QUIDELORTHO CORP has an Investment Rating of SELL; a target price of $36.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetQDEL: Lowering target price to $34.00
QUIDELORTHO CORP has an Investment Rating of SELL; a target price of $34.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice Target